| Literature DB >> 12606243 |
Ravi Kumar Kurup1, Parameswara Achutha Kurup.
Abstract
A family with a high prevalence of Parkinson's disease, schizophrenia, neoplasms, syndrome-X, rheumatoid arthritis and epilepsy has been described. The psychological behavioural patterns of the family were as follows--creativity and high IQ, hypersexual behaviour, reduced appetite and eating behaviour, insomnia and reduced sleep patterns, increased tendency for spirituality, increased tendency for addiction, less of bonding and affectionate behaviour and left handedness. Digoxin, an endogenous Na(+)-K(+) ATPase inhibitor secreted by the hypothalamus, was found to be elevated and RBC membrane Na(+)-K(+) ATPase activity was found to be reduced in all the disorders and in the indexed family studied. Hypothalamic digoxin can modulate conscious perception and its dysfunction may lead to schizophrenia. Digoxin can also preferentially upregulate tryptophan transport over tyrosine resulting in increased levels of depolarising tryptophan catabolites - serotonin, quinolinic acid, strychnine and nicotine and decreased levels of hyperpolarising tyrosine catabolites dopamine, noradrenaline and morphine contributing to membrane Na(+)-K(+) ATPase inhibition in all the above disorders and the indexed family. Digoxin induced membrane Na(+)-K(+) ATPase inhibition can result in increased intracellular Ca(2+) and reduced Mg(++) levels leading to glutamate excitotoxicity, oncogene activation and immune activation. Digoxin induced altered Ca(++)/Mg(++) ratios, reduced ubiquinone and increased dolichol can affect glycoconjugate metabolism, membrane formation and structure and mitochondrial function leading to the diverse disorders described above including those in the indexed family. The isoprenoid pathway and neurotransmitter patterns were compared in right-handed/left hemispheric dominant and left-handed/right hemispheric dominant individuals. The biochemical patterns in the indexed family and the diverse disorders studied correlated with those obtained in right hemispheric dominance. The hyperdigoxinemic state indicates right hemispheric dominance. Hypothalamic digoxin can thus function as the master conductor of the neuroimmunoendocrine orchestra and co-ordinate the functions of various cellular organelles.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12606243 PMCID: PMC7125598 DOI: 10.1016/s0306-9877(02)00382-1
Source DB: PubMed Journal: Med Hypotheses ISSN: 0306-9877 Impact factor: 1.538
Concentration of serum digoxin, dolichol, magnesium and ubiquinone and RBC membrane Na+–K+ ATPase activity
| Groups | HMG CoA reductase ratio of HMG CoA/mevalonate | Digoxin (ng/dl) | Dolichol (μg/dl) | Ubiquinone (μg/dl) | Na+–K+ ATPase (μg/pi/mg protein) | Magnesium (mg/dl) |
|---|---|---|---|---|---|---|
| 1. Control | 1.15±0.12 | 12.80±1.09 | 39.1±2.36 | 144.2±8.65 | 5.04±0.221 | 2.40±0.24 |
| 2. Epilepsy | 0.884±0.075 | 23.05±1.76 | 77.06±4.6 | 82.97±6.64 | 1.48±0.139 | 2.08±0.11 |
| 3. PD | 0.810±0.76 | 20.90±1.41 | 120.9±9.65 | 91.40±5.92 | 1.51±0.142a | 2.13±0.12 |
| 4. Schizophrenia | 0.75±0.06 | 15.13±1.13 | 67.5±5.4 | 89.33±5.36 | 1.24±0.130 | 1.81±0.12 |
| 5. CNS glioma | 0.746±0.06 | 21.54±1.47 | 69.8±4.19 | 101.6±8.13 | 1.94±0.18 | 2.16±0.22 |
| 6. MS | 0.705±0.069 | 29.15±2.19 | 54.2±3.63 | 82.85±4.89 | 0.313±0.023 | 2.11±0.15 |
| 7. HIV infection | 0.78±0.07 | 22.02±1.21 | 47.9±4.02 | 94.31±8.27 | 1.11±0.120 | 1.56±0.11 |
| 8. Syndrome-X | 0.89±0.06 | 29.95±2.36 | 44.2±1.98 | 116.8±5.6 | 1.05±0.12 | 1.53±0.11 |
| 9. Down’s syndrome | 0.87±0.075 | 19.05±1.01 | 43.8±2.98 | 90.40±5.92 | 0.349±0.26 | 1.79±0.12 |
| 10. Familial hyperdigoxinemia | 0.82±0.065 | 20.05±1.02 | 62.8±2.96 | 87.40±5.91 | 0.367±0.25 | 1.69±0.13 |
Mean of the values from 15 samples ±SD. Groups 2–10 have been compared with group 1.
p less than 0.01.
Tyrosine and tryptophan catabolic patterns in neuropsychiatric disorders
| Group | Tryptophan (mg/dl) | Tyrosine (mg/dl) | 5 HT (μg/dl) | Dop (ng/dl) | Norepi (ng/dl) | QA (ng/dl) |
|---|---|---|---|---|---|---|
| 1. Control | 1.11±0.08 | 1.14±0.09 | 20.9±1.9 | 12.89±0.67 | 45.15+2.35 | 370.60±21.07 |
| 2. CNS glioma | 2.05±0.07a | 1.01±0.07a | 48.9±3.9a | 8.43±0.44a | 33.54±1.78a | 655.73±48.8a |
| 3. MS | 1.99±0.07a | 0.929±0.06a | 92.1±7.1a | 8.68±0.52a | 31.52±1.38a | 646.92±52.93a |
| 4. Epilepsy | 1.96±0.09a | 0.883±0.05a | 59.5±4.6a | 8.53±0.53a | 34.18±1.11a | 549.34±41.21a |
| 5. PD | 1.66+0.06a | 0.901+0.06a | 77.8+5.6a | 8.45+0.44a | 34.85+1.17a | 645.53+52.64a |
| 6. Schizophrenia | 2.10+0.09a | 0.862+0.05a | 46.6+3.7a | 8.44±0.45a | 37.52±0.83a | 599.28±52.64a |
| 7. Syndrome-X | 1.80±0.06a | 0.935±0.06a | 52.8±4.8a | 8.92±0.51a | 32.26±1.85a | 655.15±44.93a |
| 8. HIV infection | 2.02±0.08a | 0.825±0.03a | 41.8±4.2a | 8.01±0.62a | 36.41±1.74a | 589.50±50.64a |
| 9. Familial hyperdigoxinemia | 2.83±0.05a | 0.842±0.06a | 44.9±3.7a | 8.76±0.42a | 30.51±1.32a | 633.52±49.42a |
Mean of the values from 15 samples ±SD. Groups 2–9 have been compared with group 1. (a) p less than 0.01.
Tryptophan and tyrosine derived alkaloids in serum of patients with neuropsychiatric disorders
| Groups | Morphine (μg/dl) | Strychnione (μg/dl) | Nicotine (μg/dl) |
|---|---|---|---|
| 1. Control | ND | ND | ND |
| 2. CNS glioma | ND | ND | 4.56±0.2a |
| 3. MS | 9.92±1.21a | 1.02±0.84a | ND |
| 4. Epilepsy | ND | 11.44±0.46a | 1.25±0.04a |
| 5. PD | ND | 9.54±0.38a | 1.07±0.03a |
| 6. Schizophrenia | ND | 0.60±0.02a | 5.28±0.21a |
| 7. Syndrome-X | ND | 2.92±0.12a | 9.72±0.84a |
| 8. Down’s syndrome | ND | 1.08±0.12a | 1.24±0.02a |
| 9. Familial hyperdigoxinemia | ND | 2.02±0.10a | 3.19±0.02a |
Mean of the values from 15 samples ±SD. Groups 2–9 have been compared with group 1. (a) p less than 0.01; ND – not detectable.
Free radical metabolism in neuropsychiatric disorders
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Control | Epilepsy | Schizo | PD | MS | Glioma | Familial | |
| MDA (μm/ml RBC) | 10.830±0.432 | 10.845±0.463 | 11.633±0.291a | 12.151±0.652a | 10.98±0.415 | 11.495±0.331a | 13.421±0.326a |
| Hydroperoxide (μm/ml RBC) | 253.60±10.18 | 245.80±10.39 | 269.88±8.23a | 273.03±7.07a | 261.95±11.94a | 266.33±6.30a | 276.84±8.18a |
| Conjugated dienes (μm/ml RBC) | 49.33±2.53 | 51.37±2.92 | 56.94±4.81a | 61.11±4.16a | 49.09±3.28 | 53.84±3.28a | 62.10±4.16a |
| Nitric oxide (μm/g protein) | 2.835±0.207 | 2.973±0.201 | 3.320±0.161a | 3.455±0.287a | 2.99±0.177 | 3.351±0.159a | 3.926±0.156a |
| Glutathione (μg/ml RBC) | 256.60±10.96 | 259.53±16.93 | 243.23±23.99a | 235.03±10.28a | 247.43±14.75 | 242.36±13.93a | 230.62±10.24a |
| Superoxide dismutase (units/mg protein) | 43.14±1.94 | 42.89±1.61 | 40.43±1.45a | 37.63±1.35a | 42.50±1.20 | 40.50±1.53a | 37.53±1.42a |
| Catalase (×10−2units/mg protein) | 3.486±0.117 | 3.416±0.180 | 3.115±0.086a | 3.200±0.149a | 3.495±0.153 | 3.305±0.121a | 2.109±0.084a |
| GSH peroxide (units/g protein) | 48.10±1.64 | 48.26±1.68 | 45.20±1.32a | 44.80±1.54a | 47.63±1.61 | 45.54±1.30a | 43.18±1.29a |
| GSH reductase (units/g protein) | 8.370±0.487 | 8.190±0.413 | 7.653±0.322a | 7.318±0.662a | 8.153±0.512 | 7.140±0.319a | 7.213±0.664a |
Groups 2–7 have been compared with group 1. (a) p less than 0.01.
Concentration of plasma glycoconjugates in neuropsychiatric disorders
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Control | Family | Epilep | PD | Schizo | MS | Glioma | |
| Total GAG (mg uronic acid/dl) | 4.57±0.408 | 16.31±0.99a | 9.99±0.961a | 10.23±0.938a | 11.9±1.07a | 8.38±0.73a | 10.63±0.99a |
| HA (mg uronic acid/dl) | 0.525±0.041 | 0.849±0.068a | 1.45±0.123a | 0.155±0.011a | 0.852±0.069a | 1.76±0.112a | 1.69±0.114a |
| HS (mg uronic acid/dl) | 0.318±0.022 | 3.18±0.110a | 1.95±0.174a | 0.557±0.049a | 0.813±0.063a | 2.105±0.112a | 2.032±0.143a |
| H (mg uronic acid/dl) | 0.284±0.019 | 2.36±0.049a | 1.60±0.014a | 0.519±0.07a | 0.527±0.042a | 1.803±0.038a | 1.33±0.052a |
| DS (mg uronic acid/dl) | 2.83±0.232 | 7.63±0.812a | 2.56±0.215a | 8.66±0.815a | 7.27±0.629a | 2.42±0.229a | 0.962±0.201a |
| ChS (mg uronic acid/dl) | 0.587±0.043 | 2.32±0.02a | 2.37±0.02a | 0.337±0.02a | 2.46±0.146a | 0.293±0.029a | 4.61±0.201a |
| Hexose (mg/g protein) | 13.55±1.26 | 18.18±1.42a | 20.91±2.01a | 22.32±1.79a | 17.20±1.08a | 27.5±2.48a | 17.21±1.48a |
| Fucose (mg/g protein | 1.65±0.149 | 2.48±0.29a | 1.98±0.186b | 1.94±0.173b | 2.23±0.223a | 2.51±0.206a | 2.10±0.191a |
| Sialic acid (mg/g protein) | 6.85±0.617 | 8.72±0.819a | 9.11±0.79a | 11.29±0.903a | 8.73±0.804a | 10.27±0.822a | 8.4±0.756a |
| Ganglioside (μg/dl) | 26.5±1.2 | 32.25±1.81a | 43.5±2.81a | 36.5±2.20a | 31.5±2.01a | 35.58±2.1a | 34.08±1.9a |
| Glycosyl diglyceride (μg/dl) | 12.5±0.72 | 19.45±1.62a | 22.5±1.60a | 21.5±1.84a | 22.25±1.78a | 20.22±1.66a | 20.08±1.84a |
| Cerebrosides (μg/dl) | 16.25±1.10 | 24.25±2.01a | 23.25±2.01a | 18.5±1.65a | 25.0±2.02a | 22.52±1.4a | 21.42±0.965a |
| Sulphatides (μg/dl) | 5.25±0.61 | 8.32±0.912a | 7.25±0.82a | 7.125±0.79a | 7.36±0.91a | 6.94±0.628a | 6.99±0.487a |
Mean of the values from 15 patients in each group + SD. Groups 2–6 have been compared with group 1. (a) p less than 0.01; (b) p between 0.01 and 0.05.
Lysosomal enzymes in neuropsychiatric disorders
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Control | Family | Epilep | PD | Schizo | MS | Glioma | |
| β-Glucuronidase (μg | 59.52±5.26 | 112.29±2.18a | 114.29±1.20a | 117.46±11.12a | 102.90±9.56a | 112.29±2.20a | 100.90±5.26a |
| β- | 2273±78.6 | 3592±83.90a | 3740±85.90a | 3209±79.50a | 3102±74.8a | 3722±80.9a | 3200±74.5a |
| Hyaluronidase (μg | 62.9±4.1 | 221.0±6.72a | 190.9±4.3a | 241±6.89a | 278±4.8a | 220±6.8a | 196.2±4.3a |
| Cathepsin-D (μg tyrosine/h/g protein) | 90.9±8.9 | 178.4±7.24a | 342.6±8.58a | 313.4±9.8a | 205.4±7.1a | 350.6±8.5a | 226.6±7.5a |
| β-Galactosidase (μg | 52.8±3.75 | 93.25±7.91a | 72.44±5.69a | 96.09±7.98a | 64.08±3.20a | 95.39±4.77a | 79.23±6.38a |
| β-Fucosidase (μg | 23.63±1.65 | 29.36±1.67a | 27.38±1.70a | 21.98±1.08 | 33.38±2.87a | 33.31±2.17a | 31.68±2.53a |
| β-Glucosidase (μg | 27.36±2.46 | 34.2±2.71a | 35.2±2.78a | 29.85±2.39 | 29.87±1.49 | 16.17±1.44a | 48.96±4.21a |
Mean of the values from 15 patients in each group ±SD. Groups 2–7 have been compared with group 1. (a) p less than 0.01.
RBC membrane composition in neuropsychiatric disorders
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|---|
| Control | Family | Glioma | MS | Epilep | Schizo | PD | |
| GAG (μg/mg protein) | 6.62±0.71 | 3.46±0.28a | 3.53±0.29a | 5.46±0.34a | 6.89±0.79 | 3.78±0.24a | 5.03±0.48a |
| Hexose (μg/mg protein) | 145.09±11.85 | 61.56±5.82a | 80.40±6.77a | 81.19±5.52a | 66.57±5.82a | 118.84±8.78a | 50.65±4.38a |
| Fucose (μg/mg protein) | 63.3±4.60 | 42.6±2.8a | 47.5±2.5a | 43.6±2.9a | 55.24±3.92b | 13.25±1.28a | 28.03±2.37a |
| Cholesterol (nmol/mg protein) | 704.33±63.09 | 839.34±49.63a | 676.31±42.27 | 684±56.77 | 510.86±41.18a | 844.5±53.62a | 624.47±33.06b |
| Phospholipid (nmol/mg protein) | 717.57±67.36 | 542.21±46.92a | 550.2±48.97a | 854±79.42 | 554.50±56.56a | 622.92±51.71b | 904.96±73.30a |
| Cholesterol:phospholipid | 0.982±0.095 | 1.228±0.11a | 1.229±0.12a | 0.801±0.054a | 0.921±0.080 | 1.36±0.086b | 0.756±0.061a |
Mean of the values from 15 patients in each group ±SD. Groups 2–7 have compared with group 1. (a) p less than 0.01; (b) p between 0.01 and 0.05.
Concentration of serum digoxin, dolichol, mangesium and ubiquinone and RBC membrane Na+–K+ ATPase activity in right hemispheric dominance and left hemispheric dominance
| Groups | HMG CoA reductase ratio of HMG CoA/mevalonate | Digoxin (ng/dl) | Dolichol (μg/dl) | Ubiquinone (μg/dl) | Na+–K+ ATPase (μg/pi/protein mg) | Magnesium (mg/fl) |
|---|---|---|---|---|---|---|
| 1. LHD | 1.15±0.12 | 12.80±1.09 | 39.1±2.36 | 144.2±8.65 | 5.04±0.221 | 2.40±0.24 |
| 2. RHD | 0.78±0.07a | 29.95±2.19a | 54.2±3.63a | 82.8±4.86a | 1.11±0.120a | 1.56±0.11a |
Mean of the values from 15 samples + SD. Group 2 has been compared with group 1. (a) p less than 0.01. RHD, Right hemispheric dominant; LHD, left hemispheric dominant.
Tyrosine and tryptophan catabolic patterns in right hemispheric dominance and left hemispheric dominance
| Group | Tyrptophan (mg/dl) | Tyrosine (mg/dl) | % HT (μg/dl) | Dop (ng/dl) | Norepi (ng/dl) | QA (ng/dl) |
|---|---|---|---|---|---|---|
| 1. LHD | 1.11±0.08 | 1.14±0.09 | 20.9±1.9 | 12.89±0.67 | 45.15+2.35 | 370.60±21.07 |
| 2. RHD | 2.05±0.07a | 0.883±0.05a | 48.9±3.9a | 8.43±0.44a | 31.54±1.78a | 655.73±48.8a |
Mean of the values from 15 samples ±SD. Group 2 has been compared with group 1. (a) p less than 0.01. RHD, Right hemispheric dominant; LHD, left hemispheric dominant.
Tryptophan and tyrosine derived alkaloids in right hemispheric dominance and left hemispheric dominance
| Groups | Morphine (μg/dl) | Strychnine (μg/dl) | Nicotine (μg/dl) |
|---|---|---|---|
| 1. LHD | 8.92±1.21 | ND | ND |
| 2. RHD | ND | 9.52±0.38a | 2.07±0.03a |
Mean of the values from 15 samples ± SD. Groups 2 has been compared with group 1. (a) p less than 0.01. ND, not detectable; RHD, Right hemispheric dominant; LHD, left hemispheric dominant.
Description of indexed family
| Diseases | Percentage |
|---|---|
| Syndrome-X | 33 |
| Systemic malignancy | 20 |
| Degenerative neuronal disorders | 16 |
| Rheumatoid arthritis | 16 |
| Schizophrenia | 23 |
| Primary generalised epilepsy | 6.6 |
| Idiopathic basal ganglia calcification (Fahr syndrome) | 23 |
| Parkinson’s disease | 8 |
Psychological profile of family members and handedness
| Behaviour | Percentage |
|---|---|
| Increased spiritual tendency | 80 |
| Decreased appetite and eating behaviour | 60 |
| High IQ and creativity | 60 |
| Decreased bonding and affectionate behaviour | 75 |
| Increased addictive behaviour | 50 |
| Insomnia and reduced sleep | 60 |
| Hypersexual behaviour | 60 |
| Left handedness/right hemispheric dominance | 40 |
Fig. 1Family tree.